DYRK2 and cancer: Inactivation of DYRK2 sensitized these cancer cells to the proteasome inhibitor Bortezomib in vitro, and blockade of Rpt3-T25 phosphorylation significantly attenuated their tumorigenecity in vivo (Guo et al., 2016).